Life Sciences Weekly - Episode 9

Recorded: August 2, 2025

Join us for Episode 9 of Life Sciences Weekly as we break down a week of volatility and progress across biotech, pharma, and medtech. With all major sector ETFs sliding—XBI down 2%, XPH off nearly 4%, and XHE dipping close to 4%—we spotlight sharp stock swings from Sarepta’s big rebound to Novo Nordisk’s record plunge.

This episode covers the latest FDA clearances, from rapid COVID-19 diagnostics and wearable heart monitors to innovative radiotherapy platforms and single-use gastroscopes. On the drug front, we highlight new approvals for rare diseases, vision impairment, and generic antidepressants, plus expanded uses for leading therapies and safety label updates for top vaccines and biologics.

We also report on rigorous FDA enforcement actions, major funding rounds in AI and radiopharma, and high-impact M&A—including Sanofi’s China deal for an RNAi rare disorder drug and Monogram Technologies’ historic autonomous robotic knee surgery, setting the stage for the future of orthopedic care.

Don’t miss this week’s industry spotlight on medtech innovation, where AI, robotics, and advanced imaging are converging to revolutionize precision surgery and patient outcomes. Tune in for expert analysis, market movers, regulatory milestones, and the trends shaping the future of life sciences. Stay curious and be well!

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly - Episode 8

Recorded: July 26, 2025

Tune in to Episode 8 of Life Sciences Weekly with host Matt Davison for a fast-paced recap of the week’s most important developments across biotech, pharma, and medtech. In this episode (July 26, 2025), Matt breaks down ETF sector performance, highlights standout market movers, and examines the biggest regulatory headlines—including major FDA approvals, special drug designations, and enforcement actions like warning letters and product recalls. Catch up on the latest funding news and capital market trends, plus a rapid-fire summary of the week’s major mergers, acquisitions, and strategic partnerships—featuring deals from Eli Lilly, Simtra BioPharma, Sanofi, and more. Finally, the industry spotlight digs into what the appointment of respected biotech veteran Dr. George Tidmarsh as the FDA’s new top drug regulator could mean for drug development and healthcare innovation in the U.S. Stay informed with concise analysis and smart commentary—ideal for professionals, investors, and anyone following cutting-edge science and industry trends.

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly - Episode 7

Recorded: June 28, 2025

In Episode 7 of Life Sciences Weekly, host Matt Davison delivers a comprehensive roundup of the week’s biggest developments in biotech, pharma, and medtech as of June 28, 2025. Tune in for a detailed market snapshot—including ETF performance and sector drivers—before diving into a packed slate of FDA approvals and regulatory actions, from Stryker’s new ankle system and the first sutureless nerve repair device to expanded Alzheimer’s imaging labels and major cancer therapy advances. The episode covers key funding rounds, including CalmWave, ForSight Robotics, and a $2B commitment to Revolution Medicines, alongside major M&A moves like Synthego’s sale, Illumina’s SomaLogic deal, and Gentell’s acquisition of Casex. In the Industry Spotlight, Matt breaks down the FDA’s removal of REMS requirements for most CAR-T cell therapies, a move set to double patient access nationwide. Whether you’re an industry insider or just curious about the future of healthcare, this episode has you covered with in-depth analysis.

With your Life Sciences Industry Guide, Matt Davison